Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Ruxolitinib in malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH): A systematic literature review

View Full Paper
Ask AI
Bookmark
Share

Authors

RPRakesh PatilAKAshwini KhadatkarSRSujay Rainchwar

Discussion

Loading...

Member takes

Overview

Systematic review shows ruxolitinib improves response rates in malignancy-associated HLH, suggesting a new therapeutic approach.

Key Points

  • This review assesses the efficacy and safety of ruxolitinib in treating malignancy-associated hemophagocytic lymphohistiocytosis.
  • Conducted a systematic literature review following PRISMA 2020 guidelines.
  • Searched databases for studies on adult patients treated with ruxolitinib for malignancy-associated HLH.
  • Included studies reporting clinical outcomes with a minimum sample size of 5.
  • Five relevant studies were included after screening 68 articles.
  • Ruxolitinib achieved an overall response rate of up to 100% in certain regimens.
  • Common toxicities included neutropenia and infections, with moderate to high methodological quality in studies.

Cite This Study

Patil et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2b3https://doi.org/10.1182/blood-2025-7213
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1HLHRUXO: A prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis2026
  2. 2Differential efficacy and safety of ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis: a systematic review and meta-analysis2026
  3. 3Accelerated response and reduced chemotherapy with ruxolitinib-based regimen therapy in pediatric hemophagocytic lymphohistiocytosis: a retrospective comparison with HLH-94 regimen2026 · 1 citations
  4. 4Nationwide survey of ruxolitinib administration for Japanese children with hemophagocytic lymphohistiocytosis2026
  5. 5Retrospective analysis of ruxolitinib as induction treatment in pediatric hemophagocytic lymphohistiocytosis2025 · 1 citations